Efficacy and safety maintained in patients who switched from Humira ® to biosimilar Cyltezo®

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news